NZ629256A - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
NZ629256A
NZ629256A NZ629256A NZ62925610A NZ629256A NZ 629256 A NZ629256 A NZ 629256A NZ 629256 A NZ629256 A NZ 629256A NZ 62925610 A NZ62925610 A NZ 62925610A NZ 629256 A NZ629256 A NZ 629256A
Authority
NZ
New Zealand
Prior art keywords
klh
saccharide
vaccine compositions
lys
peptide conjugate
Prior art date
Application number
NZ629256A
Other languages
English (en)
Inventor
Ferhana Zaman
Lavinia Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Syed Saleem Ahmed
Iii John Joseph Buckley
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of NZ629256A publication Critical patent/NZ629256A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ629256A 2009-12-22 2010-12-08 Vaccine compositions NZ629256A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (1)

Publication Number Publication Date
NZ629256A true NZ629256A (en) 2016-02-26

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ629256A NZ629256A (en) 2009-12-22 2010-12-08 Vaccine compositions
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Country Status (13)

Country Link
US (3) US20130034573A1 (enExample)
EP (2) EP2515934B1 (enExample)
JP (2) JP6007105B2 (enExample)
KR (1) KR20120120185A (enExample)
CN (2) CN102762224A (enExample)
AU (1) AU2010334428B2 (enExample)
CA (1) CA2785585A1 (enExample)
IL (1) IL220308A0 (enExample)
MX (1) MX337070B (enExample)
NZ (2) NZ629256A (enExample)
RU (1) RU2581020C2 (enExample)
SG (2) SG181628A1 (enExample)
WO (1) WO2011077309A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2769629T3 (es) * 2010-02-21 2020-06-26 Bayer Healthcare Llc Procedimiento de activación y conjugación de biomoléculas
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
AU2019305221B2 (en) * 2018-07-19 2024-11-07 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (enExample) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US5972623A (en) * 1997-07-31 1999-10-26 Metra Biosystems, Inc. Collagen-peptide assay method
DK1007546T3 (da) * 1997-08-27 2009-03-16 Novartis Vaccines & Diagnostic Molekylære mimetika af meningokok-B-epitoper
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
ES2352668T3 (es) * 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
US7736644B2 (en) * 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
BRPI0609932A2 (pt) * 2005-05-24 2011-10-11 Neovacs métodos para preparar um produto imunogênico anti-tnfalfa e para preparar uma composição de vacina, produto imunogênico anti-tnfalfa, composição imunogênica, e, composição de vacina
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
MX2010001684A (es) * 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations

Also Published As

Publication number Publication date
SG181628A1 (en) 2012-07-30
WO2011077309A3 (en) 2011-10-06
AU2010334428A1 (en) 2012-07-05
EP2515934A2 (en) 2012-10-31
IL220308A0 (en) 2012-07-31
RU2581020C2 (ru) 2016-04-10
US20190365886A1 (en) 2019-12-05
NZ600978A (en) 2014-08-29
US20130034573A1 (en) 2013-02-07
CN107412754A (zh) 2017-12-01
EP2515934B1 (en) 2017-05-17
JP6007105B2 (ja) 2016-10-12
JP6146927B2 (ja) 2017-06-14
EP3257525A2 (en) 2017-12-20
CA2785585A1 (en) 2011-06-30
JP2013515049A (ja) 2013-05-02
EP3257525A3 (en) 2018-02-28
US20150087815A1 (en) 2015-03-26
JP2015180667A (ja) 2015-10-15
KR20120120185A (ko) 2012-11-01
RU2012131162A (ru) 2014-01-27
AU2010334428B2 (en) 2015-05-21
MX2012007283A (es) 2012-07-30
SG10201408505SA (en) 2015-02-27
CN102762224A (zh) 2012-10-31
WO2011077309A2 (en) 2011-06-30
MX337070B (es) 2016-02-11

Similar Documents

Publication Publication Date Title
MX2013001527A (es) Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
MX2012001124A (es) Formulacion subcutanea de anticuerpo anti-her2.
NZ604186A (en) Ige ch3 peptide vaccine
PH12013500333A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
MX2012005863A (es) Formulaciones de anticuerpos.
MX2012006831A (es) Formacion de anticuerpos.
WO2009022157A3 (en) Peptide with improved solubility
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MY165831A (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity
EP3778917A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
AR077942A1 (es) Variantes de glucoamilasa
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
WO2010040096A3 (en) Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease
WO2008079973A9 (en) Egfr binding peptides and uses thereof
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
WO2011066291A3 (en) Lyophilization methods, compositions, and kits
EP4296361A3 (en) Immunogenic composition
BRPI0820494A8 (pt) Métodos para preparar capecitabina e composto de carbonato de trialquila rico em beta-anômero usado no mesmo
WO2007014258A3 (en) Growth hormone secretagogues
EP1592443A4 (en) IMPROVEMENTS IN VACCINES AGAINST ANTHRAX AND METHODS OF ADMINISTRATION
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
WO2010141824A3 (en) Use of targeted nitroxide agents in bone healing
MX2009000756A (es) Uso de multiples secuencias potenciadoras de la transformacion para mejorar la eficiencia de la transformacion en planta.
BRPI0921286A8 (pt) Composição imunogênica com múltiplos componentes para a prevenção de doença por estreptococos beta-hemolíticos (bhs).
WO2009105780A3 (en) Mntf peptide compositions and methods of use

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 DEC 2017 BY IN-LEGAL LIMITED

Effective date: 20160622

LAPS Patent lapsed